BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-0.11%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$7.97B
AUM Growth
+$7.97B
(-9.3%)
Cap. Flow
+$3.4M
Cap. Flow
% of AUM
0.04%
Top 10 Holdings %
Top 10 Hldgs %
77.13%
Holding
96
New
12
Increased
15
Reduced
7
Closed
7
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$78.5M |
| 2 |
Revolution Medicines
RVMD
|
$77.4M |
| 3 |
Edgewise Therapeutics
EWTX
|
$49.7M |
| 4 |
Denali Therapeutics
DNLI
|
$23.1M |
| 5 |
Celcuity
CELC
|
$22M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$242M |
| 2 |
Immunocore
IMCR
|
$65.4M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$20.9M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
$14.6M |
| 5 |
ARS Pharmaceuticals
SPRY
|
$11M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $2.06B | 25.86% | 36,179,665 +543 | +0% | +$30.9K |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.65B | 20.73% | 10,568,897 | – | – |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $793M | 9.94% | 42,864,612 | – | – |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $526M | 6.6% | 1,969,798 | – | – |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $277M | 3.48% | 6,398,365 | – | – |
|
|
6
Revolution Medicines
RVMD
$7.1B
| $243M | 3.05% | 7,549,249 +2,400,592 | +47% | +$77.4M |
|
7
Kymera Therapeutics
KYMR
$2.95B
| $241M | 3.02% | 5,995,928 | – | – |
|
8
AbCellera Biologics
ABCL
$1.25B
| $125M | 1.56% | 27,525,640 +4,615,887 | +20% | +$20.9M |
|
|
BCYC
9
Bicycle Therapeutics
BCYC
$511M
| $123M | 1.54% | 4,942,823 +3,152,433 | +176% | +$78.5M |
|
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $107M | 1.34% | 5,840,059 +2,727,273 | +88% | +$49.7M |
|
|
11
Immunocore
IMCR
$1.62B
| $98.5M | 1.24% | 1,515,318 -1,005,413 | -40% | -$65.4M |
|
12
Kodiak Sciences
KOD
$478M
| $91.1M | 1.14% | 17,310,490 | – | – |
|
13
Roivant Sciences
ROIV
$8.15B
| $78.1M | 0.98% | 7,413,834 -179,190 | -2% | -$1.89M |
|
14
Replimune Group
REPL
$422M
| $78M | 0.98% | 9,545,336 | – | – |
|
|
15
Denali Therapeutics
DNLI
$2.23B
| $76.6M | 0.96% | 3,731,695 +1,124,499 | +43% | +$23.1M |
|
16
Entrada Therapeutics
TRDA
$208M
| $68.9M | 0.86% | 4,865,819 | – | – |
|
17
Akero Therapeutics
AKRO
$3.74B
| $68.5M | 0.86% | 2,713,205 +344,827 | +15% | +$8.71M |
|
18
Ultragenyx Pharmaceutical
RARE
$2.89B
| $68.5M | 0.86% | 1,466,547 | – | – |
|
19
Immatics
IMTX
$619M
| $67.7M | 0.85% | 6,443,398 +604,545 | +10% | +$6.35M |
|
|
CERE
20
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $67.6M | 0.85% | 1,600,000 | – | – |
|
21
argenx
ARGX
$43.6B
| $59.5M | 0.75% | 151,215 | – | – |
|
22
Nurix Therapeutics
NRIX
$714M
| $57.1M | 0.72% | 3,882,125 | – | – |
|
23
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $55.4M | 0.7% | 2,809,577 | – | – |
|
24
BioCryst Pharmaceuticals
BCRX
$1.74B
| $51.4M | 0.65% | 10,126,176 | – | – |
|
|
JBIO
25
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $49.7M | 0.62% | 1,680,517 | – | – |
|